case_images: PMC9935568_01
case_images: Pathology, the sequencing reads of EGFR p.773_774dup, dynamic imaging of the space-occupying lesion on the left lung during the treatment. (A) Pathological findings revealed the lesion on the left lung was moderate-differentiated adenocarcinoma. H.E.: hematoxylin-eosin staining. Scale bars represent 250 mum (left) and 100 mum (right), respectively. (B) Immunohistochemistry (IHC) showed positive expression of thyroid transcription factor 1 (TTF1) and Napsin A. Scale bars represent 250 mum (left and right). (C) Visualization of EGFR p.773_774dup mutation using the Integrated Genomics Viewer (IGV) browser. (D) CT images showed that the patient's condition remained stable after receiving furmonertinib plus anlotinib. CT: computed tomography.
case_images: fphar-14-1053805-g001.jpg
case_images: PMC9935568_01_fphar-14-1053805-g001.jpg
case_images: F1
case_images: The pathology confirmed that the lesion on the left lung was moderate-differentiated adenocarcinoma (Figure 1A). Immunohistochemistry (IHC) showed positive expression of thyroid transcription factor 1 (TTF1) and Napsin A (Figure 1B). The sequencing reads of EGFR are demonstrated in Figure 1C. According to the latest follow-up on 30 May 2022, the patient's condition was evaluated as a SD based on thoracic CT (Figure 1D).
case_images: Case timeline.
case_images: fphar-14-1053805-g002.jpg
case_images: PMC9935568_01_fphar-14-1053805-g002.jpg
case_images: F2
case_images: The case timeline is shown as Figure 2.